Claudia A Chiriboga - JoVE Visualize

Showing results (41-50 of 45) with videos related to

Pageof 5

Sort By:

You have reached the last page of results.This site can display upto 45 results.

The Lancet. Neurology|March 20, 2021

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trialJohn W Day, Richard S Finkel, Claudia A Chiriboga, et al.

Contemporary Clinical Trials Communications|August 11, 2018

Recruitment & retention program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA!Amy Bartlett, Stephen J Kolb, Allison Kingsley, et al.

Annals of Neurology|November 18, 2017

Natural history of infantile-onset spinal muscular atrophyStephen J Kolb, Christopher S Coffey, Jon W Yankey, et al.

Annals of Clinical and Translational Neurology|February 23, 2016

Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker studyStephen J Kolb, Christopher S Coffey, Jon W Yankey, et al.

JAMA Neurology|March 24, 2020

Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical TrialsMerit Cudkowicz, Marianne K Chase, Christopher S Coffey, et al.

Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:

Pageof 5

You have reached the last page of results.This site can display upto 45 results.

The Lancet. Neurology|March 20, 2021

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trialJohn W Day, Richard S Finkel, Claudia A Chiriboga, et al.

Contemporary Clinical Trials Communications|August 11, 2018

Recruitment & retention program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA!Amy Bartlett, Stephen J Kolb, Allison Kingsley, et al.

Annals of Neurology|November 18, 2017

Natural history of infantile-onset spinal muscular atrophyStephen J Kolb, Christopher S Coffey, Jon W Yankey, et al.

Annals of Clinical and Translational Neurology|February 23, 2016

Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker studyStephen J Kolb, Christopher S Coffey, Jon W Yankey, et al.

JAMA Neurology|March 24, 2020

Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical TrialsMerit Cudkowicz, Marianne K Chase, Christopher S Coffey, et al.

Pageof 5